RedHill Settles Movantik(R) Apotex Patent Litigation
Redhill Biopharma Ltd. - American Depositary Shares (RDHL)
US:NASDAQ Investor Relations:
ir.redhillbio.com/investor-relations
Company Research
Source: Accesswire
RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with ApotexTEL AVIV, ISRAEL and RALEIGH, NC / ACCESSWIRE / July 22, 2021 / RedHill Biopharma Ltd. (Nasdaq:RDHL) ('RedHill' or the 'Company'), a specialty biopharmaceutical company, today announced that RedHill Biopharma Inc., AstraZeneca AB and AstraZeneca Pharmaceuticals LP ('AstraZeneca') and Nektar Therapeutics have entered into a settlement and license agreement with Apotex, Inc. and Apotex Corp. ('Apotex') resolving their patent litigation in the U.S. in response to Apotex's Abbreviated New Drug Application ('ANDA') seeking approval by the US. Food and Drug Administration ('FDA') to market a generic version of Movantik® (naloxegol).RedHill acquired from AstraZeneca in April 2020 the global rights to Movantik, excluding Europe and Canada.Under the terms of the settlement agreement, Apotex may not sell a generic version of Movantik in the U.S. until October 1, 2030 (subject to U.S. FDA approval) or earlier under
Show less
Read more
Impact Snapshot
Event Time:
RDHL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDHL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDHL alerts
High impacting Redhill Biopharma Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
RDHL
News
- RedHill Biopharma Ltd. (NASDAQ: RDHL) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022) [Yahoo! Finance]Yahoo! Finance
- Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 | DelveInsightPR Newswire
- Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 | DelveInsightPR Newswire
- RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights [Yahoo! Finance]Yahoo! Finance
RDHL
Sec Filings
- 4/18/24 - Form POS
- 4/8/24 - Form 6-K
- 4/8/24 - Form 20-F
- RDHL's page on the SEC website